Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq:EWTX) granted inducement stock options on May 29, 2026 to 4 new non-executive employees under its 2024 Inducement Equity Incentive Plan.

The options cover 74,000 shares at an exercise price of $34.16 per share and follow a four-year vesting schedule under Nasdaq Listing Rule 5635(c)(4).

AI-generated analysis. Not financial advice.

Key Figures

Inducement option shares: 74,000 shares New employees: 4 employees Option exercise price: $34.16 per share +3 more

6 metrics

Inducement option shares 74,000 shares Stock options granted to 4 new non-executive employees on May 29, 2026

New employees 4 employees Recipients of inducement stock option grants

Option exercise price $34.16 per share Exercise price equal to closing price on May 29, 2026 grant date

Initial vesting tranche 25% of shares Vests on one-year anniversary of each employee’s start date

Ongoing vesting rate 1/48th monthly Remaining option shares vest monthly after first-year cliff

Inducement plan year 2024 Grants made under 2024 Inducement Equity Incentive Plan

Market Reality Check

Price: $37.25 Vol: Volume 2,535,542 is 1.6x ...

high vol

$37.25 Last Close

Volume Volume 2,535,542 is 1.6x the 20-day average 1,581,782, indicating elevated trading activity. high

Technical Trading above the 200-day MA of 24.75 with a price of 37.25, still within 8.62% of the 52-week high.

Peers on Argus

EWTX fell 7.48% while close peers were mixed: VERA -9.23%, VRDN -4.28%, ARDX -2....

1 Up

EWTX fell 7.48% while close peers were mixed: VERA -9.23%, VRDN -4.28%, ARDX -2.99%, AUPH +1.92%, PHVS +0.10%. Momentum scanner flagged only SRPT at +0.37%, suggesting today’s move appears more stock-specific than a coordinated sector rotation.

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jun 01	Business sale deal	Positive	+17.9%	Servier agreed to acquire muscular dystrophy business for up to $2.65B.
Jun 01	Strategic refocus	Positive	+17.9%	Company to sell sevasemten and refocus on cardiovascular pipeline.
May 12	Conference appearance	Neutral	-1.6%	Announcement of presentation at RBC Global Healthcare Conference.
May 07	Q1 2026 earnings	Negative	-3.8%	Reported larger net loss despite strong cash; ongoing R&D spend.
May 04	Inducement grants	Neutral	+2.7%	Inducement stock options totaling 266,000 shares to new employees.

Pattern Detected

Recent major strategic news (business sale to Servier) saw a strong positive price reaction, while routine items like conferences and earnings have produced modest negative or small positive moves, indicating larger strategic catalysts have driven upside.

Recent Company History

Over the last month, Edgewise has reported several material developments. On Jun 1, 2026, Servier agreed to acquire its muscular dystrophy business, including sevasemten, for up to $2.65 billion, producing a +17.86% move and signaling a strategic pivot toward the cardiovascular pipeline. Earlier in May, Q1 2026 earnings highlighted a $49.0M net loss and cash of $499.6M, which coincided with a modest decline. Prior inducement grants on Apr 30, 2026 of 266,000 shares had a small positive reaction, suggesting such grants have not been a major overhang historically.

Market Pulse Summary

This announcement details routine equity compensation: inducement stock options for 74,000 shares gr...

Analysis

This announcement details routine equity compensation: inducement stock options for 74,000 shares granted to four new non-executive employees at an exercise price of $34.16, matching the market close on the grant date. The options vest 25% after one year, then 1/48th monthly, under the 2024 Inducement Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4). In the broader context, recent events such as the Servier transaction and Q1 2026 results have been more significant drivers of the company’s trajectory than similar inducement grants.

Key Terms

inducement stock options, equity incentive plan, nasdaq listing rule 5635(c)(4)

3 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 74,000 shares..."

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

equity incentive plan financial

"...pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan")."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

nasdaq listing rule 5635(c)(4) regulatory

"...granted as inducements material to these employees... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").   

Each inducement stock option has an exercise price of $34.16 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: edgewisetx.com or follow us on LinkedIn and X.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302790649.html

SOURCE Edgewise Therapeutics

FAQ

What inducement stock options did Edgewise Therapeutics (EWTX) grant on May 29, 2026?

Edgewise Therapeutics granted inducement stock options for 74,000 shares of common stock to four new non-executive employees. According to Edgewise, these options were issued under its 2024 Inducement Equity Incentive Plan as a material inducement to employment.

What is the exercise price of the new Edgewise Therapeutics (EWTX) inducement options?

The inducement stock options have an exercise price of $34.16 per share. According to Edgewise, this price equals the closing price of its common stock on the May 29, 2026 grant date, aligning the awards with prevailing market value.

How do the Edgewise Therapeutics (EWTX) inducement stock options vest for new employees?

The options vest over four years, with 25% vesting on the first employment anniversary and the remainder monthly. According to Edgewise, one forty-eighth of the shares vests each month thereafter, contingent on continued service with the company.

Why were the Edgewise Therapeutics (EWTX) inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as material inducements for the employees to join Edgewise, consistent with Nasdaq Listing Rule 5635(c)(4). According to Edgewise, each award is governed by the 2024 Inducement Equity Incentive Plan and related agreements.

Who received the new Edgewise Therapeutics (EWTX) inducement stock options in May 2026?

Four new non-executive employees received the inducement stock options. According to Edgewise, these grants were tied to the start of their employment and structured to encourage long-term alignment through a multi-year vesting schedule under the Inducement Plan.